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• Disclosure of Relevant Financial Relationships: The 
presenter has no financial relationships to disclose.
• Disclosure of Off-Label and /or Investigative Uses: 
The presenter(s) will not discuss off label use and /or 
investigational use in this presentation.
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Have You Ever …
• Referred a patient for genomic testing?
• Had a patient ask about the benefits of genomic 
testing?





• Understand the background of genomics related to 
Primary Care.
• Discuss the implications of genomics and 
pharmacogenomics for Primary Care.
• Characterize the clinical activity and attitudes 




• Study of all genes in an organism including.
o Nuclear and extranuclear genes (DNA, mRNA, 
protein)
o Mapping and sequencing of genes




• The genome refers to 
the complete set of 
DNA in an organism.
• Any single gene is 
expressed in a protein.
• The proteome refers to 
all the proteins in a cell 
or an organism.
• The interaction of 
proteins within the 
proteome and with the 
environment define the 






• HGP formally started in 1993 and ended in 2003.
• The project goals was to discover the estimated 
20,000-25,000 human genes and their component 




• Genetic variation necessary for survival of our 
species.
• Maladaptive genetic variation comes to our 
attention as disease.
• Complex disease is a result of the interaction 






• Personalized Medicine proposes the customization 
of an individual’s healthcare based primarily on 
his/her genome.
• Personalized Medicine suggests that knowing a 
patient’s genome will allow the patient and his/her 





o Genomic markers of disease risk that may 
allow patients to make choices about 
lifestyle, environment, and treatment.
• Pharmacogenomics
o Choosing medications based on 
genomics to
• Enhance benefit by matching the medicine to 
the patient.







• Analytical validity – genomic test results need to be 
accurate and reliable.
• Clinical validity – reliable results are of consistent 
clinical significance.
• Clinical utility – there is a clear benefit for 
intervention based on genomic test results.








• Tier 1 – recommended for clinical 
use by evidence-based panels and 
supported by systematic review of 
evidence.
• Tier 2 – validity and promising 
evidence of clinical utility, but lack 
evidence-based 
recommendations.
• Tier 3 – inadequate validity or utility.
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Single‐Gene Disease
• Single-gene disorders tend to present as severe 
disease that is seen early in life (e.g. cystic fibrosis).
• Inheritance of single-gene disorders is Mendelian.
• Many single-gene disorders are so severe that 
progeny dies in utero.






o Fetal Cells in Maternal Blood (FCMB)
o Transcervical retrieval of trophoblasts
o Chorionic Villus sampling





• Complex disease is much more frequent than 
single-gene disease.
• Complex disease (cancer, heart disease, diabetes, 
etc.) are the major contributors to morbidity and 
mortality in developed and developing countries.
• Complex disease is typically the result of multiple 
gene products interacting with each other and with 
the environment.




• A single-gene disorder is usually  expressed early in 
development and, therefore, may have limited 
prevention and treatment options.
• Complex genetic disease is slow developing, and 













• Because of its slow development, complex diseases 
can be treated by
o Changing the environment (e.g. lifestyle)
o Early intervention (e.g. early screening, removing 
a precancerous lesion)




• Pharmacogenomics (PGx) is the study of how 
individual genetic differences affect drug response.
o Predict benefit
o Anticipate adverse reactions
• The ultimate aim of PGx is to use a patient’s 
genome to use only those drugs that would be 


























• Human Epidermal  Growth Factor Receptor 2 
(HER2/neu) testing of patients with metastatic 
breast cancer to determine responsiveness to 
trastuzumab (Herceptin).
• Guided warfarin dosing by testing for Cytochrome 
P450 2C9 (CYP2C9) and Vitamin K Epoxide 





• Genomically-guided treatment would allow choice 
of the most effective medications for patients.
• Likewise, we would avoid using medication when 
the individual’s genomics suggests the risk of 
adverse effects.





• Primary Care Physicians Experience and 
Confidence with Genetic Testing and Perceived 
Barriers to Genomic Medicine. Journal of Family 
Medicine. 2015;2(2). 
o Chambers CV, Axell-House DB, Mills G, Bittner-Fagnan H, Rosenthal MP, 




















































































o Identify genomic data with high validity and 
clinical utility (i.e. Tier 1 data).
o Develop structured data storage for EHRs.
o Integrate genomic data into condition-specific, 
rules-based decision support.
o Provide the decision support to patients and 
clinician at the point of care.
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Juengst E, et al. After the revolution? Ethical and social challenges in






o“We tend to overestimate the effect 
of a technology in the short run and 
underestimate the effect in the long 
run.”
• Roy Amara, Institute for the Future
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